<SEC-DOCUMENT>0001178913-16-005731.txt : 20160623
<SEC-HEADER>0001178913-16-005731.hdr.sgml : 20160623
<ACCEPTANCE-DATETIME>20160623070013
ACCESSION NUMBER:		0001178913-16-005731
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160623
FILED AS OF DATE:		20160623
DATE AS OF CHANGE:		20160623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		161727543

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1618658.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto" align="center">
</div>

<div>&#160;</div>

<div>
<div id="DSPFPageHeader">
<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>
</div>

<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule 13a-16 or 15d-16</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">For the Month of June, 2016</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Commission File Number 001-35948</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">Kamada Ltd.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7 Sapir St.</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><br>
</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kiryat Weizmann Science Park</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><br>
</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.O Box 4081</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><br>
</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ness Ziona 74140</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><br>
</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Israel</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><br>
</font> &#160;(Address of principal executive offices)</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Form 20-F <font style="FONT-FAMILY: 'Wingdings 2', serif; FONT-SIZE: 10pt">T</font>&#160;&#160; Form 40-F <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Yes <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font>&#160;&#160; No <font style="FONT-FAMILY: 'Wingdings 2', serif; FONT-SIZE: 10pt">T</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82&#8209;____</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Registrant&#8217;s Form S-8 Registration Statement File No. 333-192720.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000001; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000001; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The following exhibit is attached:</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">99.1</font><font style="WIDTH: 36pt; DISPLAY: inline-block; FONT-SIZE: 1px" id="TRGRRTFtoHTMLTab">&#160;</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">News Release: Kamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and Medical Director for Pulmonary Diseases</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000001; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000001; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; BORDER-COLLAPSE: separate; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z955e8a4c4ad64387967939027ce8d4b3" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%" valign="top">Date: June 23, 2016</td>
<td style="WIDTH: 38%" valign="top" colspan="2"><strong> </strong>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><strong>KAMADA LTD.</strong></div>
</td>
<td style="WIDTH: 12%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 3%" valign="top">&#160;</td>
<td style="WIDTH: 35%" valign="top">&#160;</td>
<td style="WIDTH: 12%" valign="top">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 50%" valign="top" align="left">
<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 3%" valign="top">
<div style="MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt">By: </div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 35%" valign="top" nowrap="nowrap" align="left">/s/&#160;Gil Efron</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 12%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 3%" valign="top">&#160;</td>
<td style="WIDTH: 35%" valign="bottom" nowrap="nowrap" align="left">Gil Efron</td>
<td style="WIDTH: 12%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 3%" valign="top">&#160;</td>
<td style="WIDTH: 35%" valign="top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Deputy Chief Executive Officer and Chief Financial Officer</div>
</td>
<td style="WIDTH: 12%" valign="top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%" valign="top">&#160;</td>
<td style="WIDTH: 3%" valign="top">&#160;</td>
<td style="WIDTH: 35%" valign="top">&#160;</td>
<td style="WIDTH: 12%" valign="top">&#160;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000001; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000001; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
<br style="LINE-HEIGHT: 1.25">
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>EXHIBIT INDEX</u></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z8733a595e39f45c9bf7745dfd1d6ce14" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal;"><u>EXHIBIT NO.</u></div>
</td>
<td style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top">
<div style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal"><u>DESCRIPTION</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">99.1</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">News Release: Kamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and Medical Director for Pulmonary Diseases</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto" align="center">
</div>

<div id="DSPFPageFooter">
<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto" align="center">
</div>

<div>&#160;</div>

<div style="text-align: right; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>Exhibit 99.1</u></div>

<div>&#160;</div>

<div id="DSPFPageHeader">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><img style="WIDTH: 399px; HEIGHT: 99px" src="image0.jpg"></div>
</div>

<div>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z0a5aa8d802f941b5983af142e3b5a925" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: bold;">Kamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical </div>

<div style="text-align: center; line-height: 1.25; font-variant: normal; font-style: normal; font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: bold;">Development and Medical Director for Pulmonary Diseases</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="zdf7b469e5304476c8db4879d6256948b" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NESS ZIONA, Israel -- June 23, 2016 </font>-- Kamada Ltd. (Nasdaq &amp; TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced the appointment of Naveh Tov, M.D., Ph.D., to the position of Vice President, Clinical Development and Medical Director for Pulmonary Diseases, effective July 1, 2016.&#160; Dr. Tov has served as Kamada&#8217;s Medical Director in a part- time consultancy role since 2007.&#160; In addition to his current responsibilities as Medical Director of the Company's pulmonology area, in his new position, Dr. Tov will now also lead Kamada&#8217;s clinical development activities.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Dr. Eran Schenker, Vice President and Medical Director, will continue to lead Kamada's medical affairs in all of our non-pulmonary specialties, focused on Immunology and specific IgGs, such as Type-1 Diabetes, Graft vs. Host Disease (GvHD), Transplantations and Anti-Rabies IgG, as well as new initiatives. Dr. Schenker will also expand his involvement in supporting Business Development and Investors Relations.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8220;Dr. Tov has been instrumental in recent years in directing Kamada&#8217;s medical affairs initiatives in the pulmonary diseases.&#160; We are excited that he will now join us on a full-time basis and will also be leading our clinical development activities, which have reached a very important and advanced stage,&#8221; said Amir London, Kamada&#8217;s Chief Executive Officer.&#160; &#8220;With a robust pipeline of late-stage clinical programs focused on multiple <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">therapeu</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">tic indications for Alpha-1 Antitrypsin (AAT), </font>including Inhaled AAT for AAT Deficiency, Cystic Fibrosis and Bronchiectasis, and Infused (IV) AAT for Type 1 Diabetes, Graft versus Host Disease (GvHD), and lung transplant, having accomplished individuals like Dr. Tov and Dr. Schenker in key leadership positions is critical to Kamada&#8217;s future success.&#8221;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Previously, Dr. Tov served in both active hospital academic and clinical positions at Bnai Zion Medical Center, Haifa, Israel.&#160; He specializes in Internal, Pulmonary and Sleep Medicine and served as Head of the Pulmonary Unit, and as Deputy of Internal Ward C, at Bnai Zion Medical Center, for 14 years.&#160; During these years, Dr. Tov served in academia and held appointments at the Bruce Rappoport School of Medicine-Technion in Haifa, Israel.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Dr. Tov is a member of the American Thoracic Society and the European Respiratory Society. He holds an M.D. and a Ph.D. from the Bruce Rappoport School of Medicine-Technion.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="text-align: left; line-height: 1.25; font-variant: normal; font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>About Kamada Ltd</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.&#160; AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company&#8217;s flagship product is Glassia&#174;, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia&#174; in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc&#8217;s BioScience business and now part of Shire plc).&#160; In addition to Glassia&#174;, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that its MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in Europe and is in Phase 2 clinical trials in the U.S. and its intravenous AAT to treat type-1 diabetes, GvHD and to prevent lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000001; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000001; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center"><img style="WIDTH: 399px; HEIGHT: 99px" src="image0.jpg"></div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z6e65dad914104697b53a47f7b0cdae6f" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="text-align: left; line-height: 1.25; font-variant: normal; font-style: italic; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>Cautionary Note Regarding Forward-Looking Statements</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.&#160; Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations.&#160; Forward-looking statements are based on Kamada&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.&#160; Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.&#160; The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONTACT:</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Kamada Contacts:</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Gil Efron</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ir@kamada.com</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Bob Yedid</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">LifeSci Advisors</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">646-597-6989</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">bob@lifesciadvisors.com</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageFooter">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto" align="center">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, 2T# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
